ATE182622T1 - Gen des von hippel-lindau (vhl) syndroms und entsprechende cdns und methoden zur detektion von trägern des entsprechenden gens - Google Patents

Gen des von hippel-lindau (vhl) syndroms und entsprechende cdns und methoden zur detektion von trägern des entsprechenden gens

Info

Publication number
ATE182622T1
ATE182622T1 AT94916774T AT94916774T ATE182622T1 AT E182622 T1 ATE182622 T1 AT E182622T1 AT 94916774 T AT94916774 T AT 94916774T AT 94916774 T AT94916774 T AT 94916774T AT E182622 T1 ATE182622 T1 AT E182622T1
Authority
AT
Austria
Prior art keywords
gene
vhl
lindau
methods
cdns
Prior art date
Application number
AT94916774T
Other languages
English (en)
Inventor
Michael I Lerman
Farida Latif
Berton Zbar
Marston Linehan
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE182622T1 publication Critical patent/ATE182622T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT94916774T 1993-05-14 1994-05-12 Gen des von hippel-lindau (vhl) syndroms und entsprechende cdns und methoden zur detektion von trägern des entsprechenden gens ATE182622T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/061,889 US5654138A (en) 1993-05-14 1993-05-14 Von hippel-lindau (VHL) disease gene and corresponding cDNA and methods for detecting carriers of the VHL disease gene

Publications (1)

Publication Number Publication Date
ATE182622T1 true ATE182622T1 (de) 1999-08-15

Family

ID=22038796

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94916774T ATE182622T1 (de) 1993-05-14 1994-05-12 Gen des von hippel-lindau (vhl) syndroms und entsprechende cdns und methoden zur detektion von trägern des entsprechenden gens

Country Status (11)

Country Link
US (2) US5654138A (de)
EP (1) EP0698093B1 (de)
JP (1) JP3650397B2 (de)
AT (1) ATE182622T1 (de)
AU (1) AU696234B2 (de)
CA (1) CA2162928A1 (de)
DE (1) DE69419748T2 (de)
DK (1) DK0698093T3 (de)
ES (1) ES2135581T3 (de)
GR (1) GR3030876T3 (de)
WO (1) WO1994026894A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312890B1 (en) * 1993-05-14 2001-11-06 The United States Of America As Represented By The Department Of Health And Human Services Partial intron sequence of von hippel-lindau (VHL) disease gene and its use in diagnosis of disease
US6013436A (en) * 1994-07-08 2000-01-11 Visible Genetics, Inc. Compositions and methods for diagnosis of mutation in the von Hippel-Lindau tumor suppressor gene
US5958684A (en) * 1995-10-02 1999-09-28 Van Leeuwen; Frederik Willem Diagnosis of neurodegenerative disease
US5789168A (en) * 1996-05-01 1998-08-04 Visible Genetics Inc. Method for amplification and sequencing of nucleic acid polymers
US5830657A (en) * 1996-05-01 1998-11-03 Visible Genetics Inc. Method for single-tube sequencing of nucleic acid polymers
US5888736A (en) * 1995-12-22 1999-03-30 Visible Genetics, Inc. Method, compositions and kit for detection and identification of microorganisms
US6214555B1 (en) 1996-05-01 2001-04-10 Visible Genetics Inc. Method compositions and kit for detection
US6083699A (en) * 1996-05-01 2000-07-04 Visible Genetics Inc. Method for bi-directional sequencing of nucleic acid polymers
DE69709087T2 (de) * 1996-05-01 2002-04-25 Visible Genetics, Inc. Verfahren zum nachweis und zur identifizierung von mikroorganismen
US6413718B1 (en) 1996-05-01 2002-07-02 Visible Genetics Inc. Method for sequencing of nucleic acid polymers
AU7125401A (en) * 2000-05-19 2001-12-03 David J Marshall Materials and methods for detection of nucleic acids
AU1317502A (en) 2000-10-14 2002-04-29 Eragen Biosciences Inc Solid support assay systems and methods utilizing non-standard bases
US7222059B2 (en) 2001-11-15 2007-05-22 Siemens Medical Solutions Diagnostics Electrophoretic trace simulator
US20050208023A1 (en) * 2002-07-19 2005-09-22 Krissansen Geoffrey W Tumor treating composition and methods
NZ520322A (en) * 2002-07-19 2005-04-29 Auckland Uniservices Ltd Tumor treating composition and methods
WO2004061077A2 (en) * 2002-12-24 2004-07-22 North Carolina State University Increasing gamete production with a gene switch
US7494467B2 (en) * 2004-04-16 2009-02-24 Ethicon Endo-Surgery, Inc. Medical system having multiple ultrasound transducers or an ultrasound transducer and an RF electrode
US9261498B2 (en) * 2005-03-17 2016-02-16 The Regents Of The University Of California Biomarker for sensitivity to mTOR inhibitor therapy in kidney cancer
WO2012166824A2 (en) * 2011-05-31 2012-12-06 Oregon Health And Science University Methods and kits that identify tumors responsive to src inhibitors
WO2013028871A1 (en) * 2011-08-23 2013-02-28 University Of South Florida Inducible mouse models of lung injury and lung diseases
CN110066874A (zh) * 2019-04-26 2019-07-30 复旦大学附属华山医院 血管母细胞瘤分型诊断试剂盒

Also Published As

Publication number Publication date
CA2162928A1 (en) 1994-11-24
JPH08511158A (ja) 1996-11-26
DE69419748T2 (de) 1999-12-09
GR3030876T3 (en) 1999-11-30
ES2135581T3 (es) 1999-11-01
DE69419748D1 (de) 1999-09-02
EP0698093A1 (de) 1996-02-28
EP0698093B1 (de) 1999-07-28
JP3650397B2 (ja) 2005-05-18
WO1994026894A1 (en) 1994-11-24
DK0698093T3 (da) 1999-11-29
AU696234B2 (en) 1998-09-03
US5654138A (en) 1997-08-05
US5759790A (en) 1998-06-02
AU6833794A (en) 1994-12-12

Similar Documents

Publication Publication Date Title
ATE182622T1 (de) Gen des von hippel-lindau (vhl) syndroms und entsprechende cdns und methoden zur detektion von trägern des entsprechenden gens
BG101687A (bg) Заместени азетидин-2-они за лечение на атеросклероза
DE69738670D1 (de) Verfahren zur oligomerisation von peptiden
DE3785788D1 (de) Vorrichtung zur bewertung der guete von reiskoernern.
ATE269974T1 (de) Identifizierung und charakterisierung von interagierenden molekülen mittels automatisierter interagierender paarung
DE69636147D1 (de) Verfahren zur herstellung von phosphorothioat-oligomeren
NO974946L (no) Universale mål for artsidentifisering
DE69636453D1 (de) Modulation der aktivität des cholesteryl-ester-transfer-proteins (cetp)
DE69202682D1 (de) System und Verfahren zur Detektieren der unerlaubten Benutzung von Identifizierern für Rechnerzugriff.
DE69932845D1 (de) Methoden zur quantifizierung von hla-dr und cd11b
SE8902532L (sv) Bestaemning av plasmaproteiner
PT81624B (pt) Metodos recombinantes para a producao de inibidores da protease serina e metodos para o isolamento dos mesmos
ATE226254T1 (de) Reagenz zur behandlung von arthritischen zustaenden
ATE290315T1 (de) Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits
NO872936D0 (no) Fremgangsmaate for rensing av gasser avgitt fra aluminiumelektrolyseovner, og beslektet utstyr.
ATE186575T1 (de) Verfahren zur identifizierung von menschlichen und tierischen zellen mit der fähigkeit zu unbegrenzter proliferation oder zur tumorbildung
ATE203766T1 (de) Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose
NO883154L (no) Fremgangsmaate for delvis kondensasjon av hydrokarbongassblandinger.
DE69638341D1 (de) Anzeigeprozessorsystem für eine punktorganisierte Anzeige von Wellenformdaten
NO970803D0 (no) Fremgangsmåte for identifisering av forbindelser egnet for behandling av autoimmune sykdommer
WO2000031299A3 (en) Method for determining nucleotide sequences using arbitrary primers and low stringency
DE68903208D1 (de) Verfahren zur thermischen behandlung von laktoferrin.
NO156714C (no) Skibremse og fremgangsmaate til festing av denne.
DE3773106D1 (de) Methode zur entschwefelung von rauchgas.
DE3673310D1 (de) Verfahren und vorrichtung zur verhinderung von ablagerungen an den waenden metallurgischer gefaesse.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee